Altis Labs Raises US$25 Million Series A Co-Led by OrbiMed and Qiming Venture Partners USA to Accelerate Clinical Development with AI Endpoints
This funding enables Altis Labs to advance AI-driven clinical endpoints, potentially accelerating drug development and enhancing medical research efficiency.
This funding enables Altis Labs to advance AI-driven clinical endpoints, potentially accelerating drug development and enhancing medical research efficiency.
Auto-scored: Low risk as a minor funding event in medical AI; mitigation is a real but partial step towards clinical advancements.